Clinical study of Gene‐Eden‐VIR/Novirin in genital herpes: suppressive treatment safely decreases the duration of outbreaks in both severe and mild cases

Clinical & Translational Med

Itzkovitz

Javaherian

2019

Self Cite

The Editor of this journal has published this Expression of Concern to alert readers that, following publication of the article [1], it came to light that there were undeclared competing interests that have a direct impact on the article and the strength of its findings. In addition, post publication peer review has indicated that the conclusions may not be supported by the results due to methodological flaws in the study. Pending further investigation of these concerns, further editorial action may be taken. The authors have not responded to any correspondence about this Expression of Concern.

Section: Expression Of Concern: Clin Trans Med (2016) 5:40 101186/s4mentioning

confidence: 99%

Expression of Concern to: Clinical study of Gene‐Eden‐VIR/Novirin in genital herpes: suppressive treatment safely decreases the duration of outbreaks in both severe and mild cases

Clinical & Translational Med

Itzkovitz

Javaherian

2019

Self Cite

“…A fourth clinical study showed that Gene-Eden-VIR/Novirin decreased the duration of genital herpes outbreaks. 18 …”

Section: Introductionmentioning

confidence: 99%

Human papillomavirus (HPV): systemic treatment with Gene-Eden-VIR/Novirin safely and effectively clears virus

Itzkovitz

Javaherian

2017

DDDT

Self Cite

PurposeThis paper reports the results of a clinical study that tested the effect of systemic treatment with the botanical product Gene-Eden-VIR/Novirin on the clearance rate (also called time to clearance) of the human papillomavirus (HPV). The study compared the clearance rate in treated and untreated individuals suffering from a symptomatic HPV infection. The data on the untreated individuals were obtained by reverse engineering of the Kaplan–Meier figures in five published papers.Materials and methodsThe study included 59 treated participants. All participants were suffering from a symptomatic HPV infection prior to the commencement of treatment. The treatment was one to four capsules of Gene-Eden-VIR/Novirin per day. The duration of treatment was 2–12 months. The study included five groups of external controls with diverse characteristics.ResultsThe mean time to clearance in Gene-Eden-VIR/Novirin-treated individuals was 5.1 months or 151.5 days (95% CI: 4.2–5.9 months or 95% CI: 125.7–177.3 days, respectively). The median time to clearance was 3.5 months. The mean time to clearance in the five untreated groups ranged from 6.9 to 20.0 months (P<0.0001 for the difference between treatment group and each untreated group). Also, 100% of the participants in the treatment group were HPV free at the end of 12 months vs 53%, 52%, 65%, 20%, and 77% in the untreated control groups. The treated participants reported no adverse experiences.ConclusionThis clinical study has two major contributions. First, it showed that systemic treatment with the natural Gene-Eden-VIR/Novirin decreased the time to HPV clearance, increased the percentage of HPV-free individuals, and caused no adverse experiences in individuals suffering from a symptomatic HPV infection. Since there are no other systemic treatments for symptomatic HPV infections, this study presents highly valuable information on the clinical effects of the first treatment in this category. Second, the study presents a new method for conducting clinical studies that addresses one of the major deficiencies associated with the practice of the randomized controlled trial method.

“…Clinical studies showed that Gene-Eden-VIR/ Novirin is a safe and effective treatment against several viruses, including the human papillomavirus (HPV), herpes simplex virus (HSV), Epstein-Barr virus (EBV), human cytomegalovirus (HCMV), and hepatitis C virus (HCV). [11][12][13][14] In another study, Polansky et al suggested that the possible broad antiviral effects of Gene-Eden-VIR/Novirin may be mediated through the treatment's effect on the immune system. 15 In the next section, we review evidence on the effects of the Gene-Eden-VIR/Novirin ingredients on the betacoronaviruses family of viruses, and specifically, the SARS-CoV virus.…”

mentioning

confidence: 99%

Effects of Gene-Eden-VIR and Novirin on SARS-CoV: Implications for COVID-19

J Evid Based Complementary Altern Med

Lori

2020

Self Cite

The coronavirus (SARS-CoV-2), which causes COVID-19, is a betacoronavirus closely related to the human severe acute respiratory syndrome (SARS)-coronavirus (SARS-CoV). The recent COVID-19 outbreak created an urgent need for treatment. To expedite the development of such treatment, pharmaceutical companies and government agencies are currently testing several existing drugs for their effect on the virus. Gene-Eden-VIR and Novirin are natural, broad-spectrum, antiviral treatments proven to be safe and effective in several clinical studies. In this article, we present evidence indicating that the 5 Gene-Eden-VIR/Novirin ingredients have anti-betacoronavirus, and specifically, anti-SARS-CoV effects. We consider this evidence as a first indication of the anti-coronavirus effects of Gene-Eden-VIR/Novirin. Next, we are planning to conduct a clinical study with users of the treatments to test the effects of Gene-Eden-VIR/Novirin on individuals at risk and those infected with the virus.